Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas
- PMID: 7521787
- DOI: 10.1002/1097-0142(19941001)74:7<1921::aid-cncr2820740716>3.0.co;2-9
Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas
Abstract
Background: Recently, it has been shown that heating paraffin embedded tumor sections in a microwave oven can reactivate an epitope of Ki-67 protein that is recognized by the monoclonal antibody MIB-1. With this technique, a close correlation was shown between the bromodeoxyuridine labeling index (BUdR LI) and the MIB-1 proliferating cell index (PCI) in corresponding regions of glioblastomas.
Methods: The reliability of the MIB-1 PCI as a marker of proliferation was evaluated in 90 cerebral gliomas. The MIB-1 immunostaining of ethanol-fixed, paraffin embedded sections of 23 moderately anaplastic astrocytomas, 22 highly anaplastic astrocytomas, 30 glioblastomas, and 15 mixed malignant gliomas was compared with the BUdR LI and, in some cases, the Ki-67 PCI.
Results: MIB-1 positive cells were detected easily in the majority of the cases, and the MIB-1 immunostaining was often superior to that of Ki-67 in individual tumors. The MIB-1 PCI was significantly higher than the Ki-67 PCI and the BUdR LI. Linear-regression analysis showed significant correlations among the three indices. The MIB-1 PCI was correlated with the BUdR LI in each group of the astrocytic tumors and mixed malignant gliomas; the MIB-1 PCI was approximately 2.4-2.8 times higher than the BUdR LI.
Conclusions: The close correlation between the MIB-1 PCI and the in vivo BUdR LI in serial sections of glioma subtypes suggests that MIB-1 immunostaining is a useful technique for analyzing the proliferative potential of individual gliomas.
Similar articles
-
Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.Acta Neuropathol. 1994;87(6):586-93. doi: 10.1007/BF00293319. Acta Neuropathol. 1994. PMID: 8091951
-
Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods.J Neurooncol. 1996 Aug;29(2):129-36. doi: 10.1007/BF00182135. J Neurooncol. 1996. PMID: 8858517
-
A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.J Neuropathol Exp Neurol. 1997 Jul;56(7):798-805. J Neuropathol Exp Neurol. 1997. PMID: 9210876
-
[A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].No Shinkei Geka. 1984 Aug;12(9):1007-18. No Shinkei Geka. 1984. PMID: 6390240 Review. Japanese.
-
The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.Pathol Oncol Res. 2006;12(3):143-7. doi: 10.1007/BF02893360. Epub 2006 Sep 23. Pathol Oncol Res. 2006. PMID: 16998593 Review.
Cited by
-
CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.Stem Cells Transl Med. 2015 Jul;4(7):822-31. doi: 10.5966/sctm.2014-0047. Epub 2015 May 27. Stem Cells Transl Med. 2015. PMID: 26019225 Free PMC article.
-
Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas.J Clin Pathol. 2005 Mar;58(3):263-8. doi: 10.1136/jcp.2004.018606. J Clin Pathol. 2005. PMID: 15735157 Free PMC article.
-
(99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.J Neurooncol. 2008 Sep;89(2):225-30. doi: 10.1007/s11060-008-9611-8. Epub 2008 May 6. J Neurooncol. 2008. PMID: 18458817
-
Cell proliferation in the post-surgical stomach, dietary salt, and the effect of H pylori eradication.J Clin Pathol. 1999 Sep;52(9):665-9. doi: 10.1136/jcp.52.9.665. J Clin Pathol. 1999. PMID: 10655987 Free PMC article.
-
Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.J Neurooncol. 1999;44(3):255-66. doi: 10.1023/a:1006398613605. J Neurooncol. 1999. PMID: 10720205
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous